Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Aeolus Pharmaceuticals (AOLS)

Add AOLS Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Sheep
Search This Board: 
Last Post: 11/17/2017 9:22:33 AM - Followers: 17 - Board type: Free - Posts Today: 0



Our strategy is to use non-dilutive capital wherever possible to develop our exciting platform of broad-spectrum catalytic antioxidant compounds in important unmet indications of national strategic importance.  We plan to continue to leverage that capital, like the investment made by U.S. government agencies, such as NIH-NIAID and NIH CounterACT, in AEOL 10150 as a medical countermeasure, to concurrently develop these promising compounds for use in significant unmet medical indications, like oncology. We are currently doing this with AEOL 10150, where we are leveraging the potential substantial government investment in research and development of AEOL 10150 as a medical countermeasure to develop the compound in oncology indications, where it would be used in combination with radiation therapy

Business Overview

 We are developing a platform of a new class of broad-spectrum catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health. These compounds, known as metalloporphyrins, scavenge reactive oxygen species ("ROS") at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme superoxide dismutase ("SOD").  While the benefits of antioxidants in reducing oxidative stress are well-known, research with our compounds indicates that metalloporphyrins can be used to affect signaling via ROS at the cellular level.  In addition, there is evidence that high-levels of ROS can affect gene expression and this may be modulated through the use of metalloporphyrins. We believe this could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation.

Our lead compound, AEOL 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.  We are leveraging the significant investment made by U.S. government agencies to develop this promising compound for use in oncology indications, where it would be used in combination with radiation therapy, and is currently in development for use as both a therapeutic and prophylactic drug. 

AEOL 10150 has previously been tested in two Phase I clinical trials with no serious adverse events reported.  Data have already been published showing that AEOL 10150 does not interfere with the therapeutic benefit of radiation therapy in prostate and lung cancer preclinical studies.  Early next year we expect to release data showing the drug's impact, if any, when used in combination with radiation and/or chemotherapy.  In mid-2011 we expect to begin Phase I/II studies in non-small cell lung cancer ("NSCLC").

AEOL 10150 is also being developed as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome ("Pulmonary Acute Radiation Syndrome" or "Lung-ARS") as well as the gastrointestinal sub-syndrome of acute radiation syndrome ("GI-ARS"), both caused by exposure to high levels of radiation due to a radiological or nuclear event.  It is also being developed for use as a countermeasure for exposure to chemical vesicants such as chlorine gas and sulfur mustard gas.  AEOL 10150 has already performed well in animal efficacy and safety studies in each of these potential indications.  A significant portion of the funding for the medical countermeasure development programs to date has come from various government entities.    Although our management expects this funding to continue, there is no guarantee that it will do so.  We have submitted proposals to the Biomedical Advanced Research and Development Authority ("BARDA") to develop AEOL 10150 as countermeasures for both Lung-ARS and cholorine gas exposure.  We are awaiting a final decision from BARDA on the contract.  If the contract from BARDA is awarded, it is expected that it will fund all of the costs to bring AEOL 10150 to FDA approval for that indication.

We have two programs underway for the development of our second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson's disease.   These programs are being funded, in part, by private foundations and government grants.


 PDF Presentation Feb 2011:



Share Structure:

60,470,718 outstanding shares as of  MAY 10,2011
200,000,000 shares authorized

~ 6 - 9 Million shares in the Float
as of Jan 26, 2011



Point of Contact:

CFO: Russell Skibsted

Public Company, Headquarters Location
26361 Crown Valley Pkwy., Ste. 150, Mission Viejo, CA 92691-7324, United States
(949)481-9825, (949)481-9829 fax

AOLS (Daily)

AOLS (Weekly)


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AOLS News: Quarterly Report (10-q) 08/14/2017 05:09:19 PM
#579   Good point was going to raise my bid tyfoidhana 11/17/17 09:22:33 AM
#578   Don't drive up the price just yet. I'm Zlinger 11/17/17 01:07:43 AM
#577   LOL, I bought 20,000 shares yesterday and 20,000 GetSeriousOK 11/16/17 08:47:26 PM
#576   Can't wait to hear more about this wonder jimbob4stocks 11/16/17 03:06:52 PM
#575   I hope this continues. I expect we should Sheep 11/16/17 10:33:25 AM
#574   lmao. As Al Bundy would say.."toaster leavin's is MERCURIAL 11/16/17 09:53:03 AM
#573   sweet...let's goooo AOLS! MERCURIAL 11/16/17 09:52:00 AM
#572   You guys are trampling all over my crumbs tyfoidhana 11/16/17 09:50:48 AM
#571   10 k buy who's going drop 10 k MADDSTACKER 11/16/17 09:50:28 AM
#570   At least they are above .10. Not jimbob4stocks 11/16/17 09:49:49 AM
#569   Nice --------------Gap! tyfoidhana 11/16/17 09:48:53 AM
#568   Real smart let's stick a wall up ... MADDSTACKER 11/16/17 09:48:04 AM
#567   0.073 x 0.12 - very thin jimbob4stocks 11/16/17 09:43:25 AM
#566   I found it on msn headline news day tyfoidhana 11/16/17 07:13:04 AM
#565   Can you post a link to that article? Zlinger 11/15/17 09:38:05 PM
#564   Absolutely! This drug is a make or jimbob4stocks 11/15/17 03:42:52 PM
#563   Could see South Korea and Japan's government ordering MADDSTACKER 11/15/17 01:20:24 PM
#562   Could well be why there looking for the tyfoidhana 11/15/17 12:02:23 PM
#561   My L2 shows a gap between .075 and jimbob4stocks 11/15/17 11:00:55 AM
#560   Seems fitting! We're on the edge of jimbob4stocks 11/15/17 11:00:06 AM
#559   Show us the money!!!! $AOLS MERCURIAL 11/15/17 10:44:58 AM
#558   Read an article yesterday pertaining to the latest tyfoidhana 11/15/17 10:39:41 AM
#557   $AOLS will have its day. AEOL10150 is jimbob4stocks 10/27/17 04:50:31 PM
#556   I prefer letting them come to me rather tyfoidhana 10/27/17 09:07:13 AM
#555   Yep. Picking up crumbs could become quite profitable here. MERCURIAL 10/27/17 09:00:38 AM
#554   Grabbed a small position here today myself I tyfoidhana 10/26/17 09:18:36 PM
#553   I only have a small position here. Just MERCURIAL 10/26/17 08:48:42 AM
#552   Mercurial, I see that you're also on the GetSeriousOK 10/25/17 06:20:37 PM
#551   Smack ETRF and get those .08's outta here. $AOLS MERCURIAL 10/13/17 02:32:27 PM
#550   It's definitely got a ton of potential. $AOLS MERCURIAL 10/11/17 02:14:48 PM
#549   I see this ticker on a number of tyfoidhana 10/11/17 02:10:13 PM
#548   I see this ticker on a number of tyfoidhana 10/11/17 02:10:12 PM
#547's been quiet...too quiet. lol $AOLS MERCURIAL 10/11/17 01:25:18 PM
#546   Looking for buyout or JV !! Imho big MADDSTACKER 10/11/17 01:16:55 PM
#545   Well not exactly, but for the most part Sheep 10/11/17 11:44:22 AM
#544   Does this get approval for humans based on tyfoidhana 10/11/17 10:51:53 AM
#543   Daily and weekly charts starting to squeeze hard tyfoidhana 10/10/17 10:27:23 PM
#542   lol ,, nuke , nuke ,nuke !!!!! Bawhhaahhaaha MADDSTACKER 10/10/17 01:15:57 PM
#541   Where'd they go? Guess we'll wait on a catastrophe. MERCURIAL 10/10/17 01:14:46 PM
#540   Yep. Bring that news tomorrow and let 'em MERCURIAL 10/09/17 03:16:58 PM
#539   Nice bids MADDSTACKER 10/09/17 03:11:47 PM
#538 mick 10/08/17 01:19:21 PM
#537   Damn, we biddin' .06's? Makes me wanna grab MERCURIAL 10/06/17 09:38:27 AM
#536   Agreed let her breath I'd like to be MADDSTACKER 10/03/17 02:28:26 PM
#535   People on the ask need to back the MERCURIAL 10/03/17 02:27:37 PM
#534   Yes sir! Sometimes traders have to chase. This MERCURIAL 10/02/17 09:33:43 AM
#533   Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistic MADDSTACKER 10/02/17 08:34:14 AM
#532   Sounds like it's a needed medicine ! All MADDSTACKER 09/30/17 02:13:22 PM
#531   doris over at the aols yahoo board has Sheep 09/29/17 04:21:11 PM
#530   Let's get $AOLS back over .10 next week. MERCURIAL 09/29/17 02:36:29 PM